Cue Biopharma has appointed Shao-Lee Lin as CEO, President and Director. Lin will succeed Lucinda Warren, Interim President and CEO.
Lin brings more than 25 years of biopharmaceutical leadership experience to the role. Prior to joining Cue, she was Founder and CEO of Acelyrin, a biotechnology company.
More recently, Lin has continued to create and advise innovative ventures, further expanding her track record of building and scaling biotechnology platforms. Earlier in her career, Lin served as Chief Scientific Officer and Head of R&D at
Horizon Therapeutics, and held leadership roles at AbbVie, Gilead Sciences and Amgen.
Pasha Sarraf, chairman of the board at Cue Biopharma, said: “Shao-Lee [has an] exceptional track record progressing breakthrough therapies from concept to clinic, combined with her disciplined approach to leading companies through growth.”
Shao-Lee Lin, newly appointed CEO, commented: “Cue represents a unique opportunity to bring meaningful medicines to patients with the advancement towards phase 1 of CUE-401, a molecule with the potential to disrupt autoimmune disease.
“We are also pleased to share today the addition of an ongoing phase 2 program to our pipeline, which will be the subject of a separate release. We believe it offers the potential of functional cure for allergic disease, and opportunity for a significant near-term inflection for the company within 2H2026.”
Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases.